Short report

Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis

A D CROCKARD, T A MCNEILL, J MCKIRGAN, S A HAWKINS

From the Departments of Microbiology and Immunobiology, and Medicine, Queen’s University of Belfast, Royal Victoria Hospital, Belfast, Northern Ireland

SUMMARY Using monoclonal antibodies Ta1 and CD25 (interleukin-2 receptor: I-2R) and flow cytometry, the levels of activated lymphocytes in the peripheral blood of 50 patients with multiple sclerosis (16 relapsing inactive; 14 relapsing active; 20 chronic progressive) and 20 normal subjects were investigated. No significant differences were observed in the percentage or absolute numbers of Ta1 and IL-2R reactive lymphocytes between the normal and multiple sclerosis patient groups, irrespective of disease activity. Monitoring peripheral blood lymphocytes with respect to these markers would appear to have little value in the management of multiple sclerosis.

During the last decade the immune status of patients with multiple sclerosis has been extensively studied and in particular the distribution and function of various monoclonal antibody defined lymphocyte subpopulations. Despite numerous investigations no clear consensus of opinion exists as to the relationship between numbers of T cells and their subsets with disease activity.1-6

More recently attention has focused on the role of activated T cells in multiple sclerosis and, using monoclonal antibodies, several investigators have demonstrated the presence of these cells in peripheral blood and cerebrospinal fluid (CSF) of multiple sclerosis patients.7-13 The monoclonal antibody Ta1 has been reported as identifying a human T cell specific activation antigen.14 Using this reagent Hafler et al9 have reported that a majority of patients with chronic progressive multiple sclerosis have elevated levels of Ta1\(^+\) cells in the peripheral blood compared with patients with stable multiple sclerosis, other neurological diseases or normal controls. In contrast, lymphocytes displaying other activation antigens (interleukin-2 receptor, IL-2R; T113) were not found to be increased. Thus it was suggested that the identification and monitoring of Ta1\(^+\) cells may provide a useful objective measurement of immunological activity in multiple sclerosis.

In this study we have investigated, using flow cytometry, the numbers of activated lymphocytes (Ta1\(^+\), IL-2R\(^+\)) in peripheral blood from a series of multiple sclerosis patients and normal subjects, with the aim of determining the levels of these cells in multiple sclerosis patients and their relevance to disease activity. In addition, a lymphocyte phenotypic profile (T, T helper, T suppressor, B, natural killer cells) was obtained in all cases.

Patients, materials and methods

Fifty patients with multiple sclerosis and 20 normal subjects were studied. All patients had clinically definite multiple sclerosis or progressive probable multiple sclerosis according to the criteria of McDonald & Halliday.15 No patients had received steroids within the previous 3 months; none had been treated with an immunosuppressive drug other than steroids. Relapsing/remitting cases (30) were classified as active (14), if they had been in relapse within the previous 1 month, with new symptoms and signs which had not previously existed, or an exacerbation of previously existing signs. The term progressive multiple sclerosis represents patients (20) who had experienced a steady deterioration in symptoms and signs over the previous 6 months without any sudden deterioration.

Heparinised blood samples (5 ml) were obtained from patients and control subjects and lymphocyte subpopulations identified using monoclonal antibodies and flow cytometry. Briefly, 100 \(\mu\)l aliquots of blood were incubated for 15 min, on ice, with 5 \(\mu\)l of the respective monoclonal antibodies: OKT11 (CD2); OKT3 (CD3); OKT4

Address for reprint requests: Dr A D Crockard, Dept. Microbiology and Immunobiology, Queen’s University of Belfast, Royal Victoria Hospital, Grosvenor Road, Belfast BT12 6BN, Northern Ireland.

Received 16 June 1987. Accepted 20 July 1987
(CD4); OKT8 (CD8); OKB7; (Ortho-Mune) or 10 µl of Leu 7; IL-2R (CD25); (Becton Dickinson). Following two washes in phosphate buffered saline (PBS) (3 min, 400 g), 100 µl of (1:20) goat anti mouse IgG-FITC (Ortho) was added to the respective preparations and a further incubation (15 min) on ice performed. Using monoclonal antibody Tal (Coulter Clone), which is directly conjugated to phycoerythrin, a 30 min staining period was employed. Appropriate controls for background staining were included in each assay. Following incubation with conjugated antibodies, all blood samples were washed twice in PBS and red cells lysed using Whole Blood Quick Stain Lysing Reagent (Coulter Immunology). The remaining leukocytes were resuspended in a 1% paraformaldehyde-PBS solution. Analyses were performed on an EPICS 541 flow cytometer (Coulter Electronics Ltd). Lymphocyte populations were identified on the basis of forward and 90° light scatter signals and gated appropriately. Single parameter log green or red signals were obtained from the gated populations. Five thousand lymphocytes were counted in each sample and the percentage of positive cells determined using the instrument’s Immuno programme.

Statistical analyses were performed using the Mann Whitney U test.

Results

The percentages and absolute numbers of Tal* and IL-2R* cells determined in the multiple sclerosis patient and normal control groups are shown in the table. No statistically significant differences were observed in either the percentages or absolute numbers of Tal* cells between the controls and multiple sclerosis patients, nor between the clinically defined patient groups. Using 2 standard deviations from the mean values obtained for Tal* cells from control subjects as the upper limit of normal (58%; 1:32 × 10⁹/l), three patients (one inactive, one active, one progressive) demonstrated increased percentages of Tal* cells (60%; 65%; 61% respectively), although the absolute number of circulating Tal* cells was not above the normal limit.

Representative fluorescence profiles obtained for Tal are shown in the fig. a, b. The most frequently observed profile was that shown in figure (a) (41/50 multiple sclerosis patients; 16/20 normals). The implications of these differences in Tal reactivity are unclear at present as we were unable to relate the profile type to other immunological or clinical features.

A low percentage of IL-2R* cells was observed in the normal (4 ± 1%) and patient groups (relapsing inactive: 3 ± 1%; relapsing active: 3 ± 1%; chronic progressive: 4 ± 1%). Again no statistically significant differences were observed between normals and patients irrespective of disease activity.

The percentages and total numbers of the respective T, T subset, B and NK cells did not differ between patient groups or between patient groups and normal controls (data not shown).

Discussion

In this study we did not observe differences in Tal reactivity in peripheral blood lymphocytes from

<table>
<thead>
<tr>
<th>Table</th>
<th>Tal and IL-2R reactive lymphocytes in peripheral blood from multiple sclerosis patients and normal subjects (Mean ± SEM)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tal</td>
</tr>
<tr>
<td>Relapsing inactive multiple sclerosis</td>
<td>(16)</td>
</tr>
<tr>
<td>Relapsing active multiple sclerosis</td>
<td>(14)</td>
</tr>
<tr>
<td>Chronic progressive multiple sclerosis</td>
<td>(20)</td>
</tr>
<tr>
<td>Normal subjects</td>
<td>(20)</td>
</tr>
</tbody>
</table>

Crockard, McNeill, McKirgan, Hawkins

Fig. Fluorescent histograms obtained for lymphocytes stained with phycoerythrin-conjugated Tal. (x axis: fluorescence intensity; y axis: relative cell number). (a) and (b): distinctive profiles observed in two multiple sclerosis patients with relapsing disease.
Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis

normal donors or multiple sclerosis patients. Similarly, in the patient groups there was no relationship between the numbers of Ta1* cells and disease activity. These findings contrast with those of Hafer et al9 who reported elevated numbers of Ta1* lymphocytes in peripheral blood of 20 of 35 patients with chronic progressive multiple sclerosis and four of 18 cases of stable or improving disease. In addition, the percentages of Ta1 reactive cells reported by these investigators were substantially lower (normals: 6 ± 1%; progressive multiple sclerosis 16 ± 1%; stable or improving multiple sclerosis 11 ± 1%) than obtained in this study (table). This discrepancy could be due to the methods used to collect fluorescent signals in the flow cytometer. In the study of Hafer et al9 analyses were based on the (less sensitive) collection of linear as opposed to the more conventional log amplified signals used in the present study.

Recently it has been reported that the Ta1 monoclonal antibody identifies antigen reactive memory T cells.16 The fact that this population may include T cells which are reactive with autoantigens makes it interesting to speculate on the possible role of these cells in autoimmune disease. However, in view of our findings of relatively high numbers of Ta1* cells and the similarity between normals and multiple sclerosis patients, further investigation of the functions of Ta1* cells is warranted.

Low levels of IL-2R lymphocytes were observed in peripheral blood of both normal donors and multiple sclerosis patients. This is a consistent finding in multiple sclerosis where increases in IL-2R+ cells are negligible or modest.9-11,13 However, significantly elevated numbers of IL-2R+ cells can be demonstrated in the CSF.10,11 Whether this reflects local activation within the CSF or recruitment from the periphery is unclear at present.

In conclusion, using two markers of lymphocyte activation (Ta1, IL-2R) we were unable to demonstrate abnormal levels of activated cells in the peripheral blood of multiple sclerosis patients irrespective of disease activity. The clinical relevance of activated T cells and their role in the pathogenesis of multiple sclerosis remain to be determined. Nevertheless future studies using additional activation markers and determination of the functional characteristics of these cells may still help to further elucidate this aspect of the immunological process in multiple sclerosis.

The authors thank Sean MacRory for technical assistance and Patricia McConnell for preparation of the manuscript. This work was supported by Action MS.

References


Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis.
A D Crockard, T A McNeill, J McKirgan and S A Hawkins

*J Neurol Neurosurg Psychiatry* 1988 51: 139-141
doi: 10.1136/jnnp.51.1.139

Updated information and services can be found at: [http://jnnp.bmj.com/content/51/1/139](http://jnnp.bmj.com/content/51/1/139)

**These include:**

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)